{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:14:47Z","timestamp":1761664487582,"version":"3.40.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Knowledge of the immunogenicity of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) in liver transplant recipients (LTRs) is mainly limited to messenger RNA (mRNA)\u2010based types. We aimed to evaluate the humoral response in LTRs and to address the use of different doses of mycophenolate (MMF) on the probability of developing anti\u2010spike immunoglobulin G (IgG). In this prospective cohort study, SARS\u2010CoV\u20102 anti\u2010spike IgG, neutralizing antibodies (NAs), and nucleocapsid protein (N) were evaluated in LTRs and healthy volunteers 21\u201390\u2009days after receiving the second vaccine dose of either ChAdOx1 (AstraZeneca), rAd26\u2010rAd5 (Sputnik V), inactivated BBIBP\u2010CorV (Sinopharm), or the heterologous combination rAd26\/mRNA\u20101273 (Sputnik V\/Moderna). We collected information regarding clinical data and vaccine side effects. After excluding three LTRs due to a positive N test, 120 LTRs and 27 controls were analyzed. No significant differences were found among groups. Overall, 24 (89%) controls and 74 (62%) LTRs were positive for anti\u2010spike IgG (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.007). Among LTRs, those immunized with rAd26\/mRNA\u20101273 presented significantly higher positive serology and NAs when compared with the homologous regimens (91% vs. 55%, <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.001; and 1182\u2009IU\/ml vs. 446\u2009IU\/ml, <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.002; respectively). In the multivariate analysis, humoral response was significantly reduced in LTRs who received higher doses of MMF (odds ratio [OR], 0.1; 95% confidence interval [CI], 0.03\u20130.3; <jats:italic toggle=\"yes\">p<\/jats:italic>\u2009&lt;\u20090.001) and with increased BMI (OR, 0.4; 95% CI, 0.2\u20130.7; <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.005); and it was significantly higher in those immunized with rAd26\/mRNA\u20101273 (OR, 13.1; 95% CI, 2.3\u201372.9; <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.003). In LTRs anti\u2010spike IgG concentrations showed a very good correlation with NA titers (<jats:italic toggle=\"yes\">R<\/jats:italic>\n                           <jats:sup>2<\/jats:sup> =\u20090.949; 95% CI, 0.919\u20130.967; <jats:italic toggle=\"yes\">p<\/jats:italic>\u2009&lt;\u20090.001). No serious adverse events were reported in either group. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> In LTRs, rAd26\/mRNA\u20101273 was independently associated with higher antibody response. Future studies are necessary to evaluate whether combining different vaccine platforms and MMF reduction may lead to a better booster response.<\/jats:p>","DOI":"10.1002\/hep4.2034","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T06:00:07Z","timestamp":1659074407000},"page":"2850-2859","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Heterologous adenovirus\u2010vector\/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-9908","authenticated-orcid":false,"given":"Manuel","family":"Mendizabal","sequence":"first","affiliation":[{"name":"Hepatology and Liver Transplant Unit,Hospital Universitario Austral,Pilar,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Ducasa","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas en Retrovirus y SIDA,CONICET\u2010Universidad de Buenos Aires,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Benencio","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas en Retrovirus y SIDA,CONICET\u2010Universidad de Buenos Aires,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Anders","sequence":"additional","affiliation":[{"name":"Hepatology and Liver Transplant Unit,Hospital Alem\u00e1n,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cairo","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit,Hospital El Cruce,Florencio Varela,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Barbero","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit,Hospital El Cruce,Florencio Varela,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Etcheves","sequence":"additional","affiliation":[{"name":"Bioars S.A.,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Alter","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hemocentro,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Scarton","sequence":"additional","affiliation":[{"name":"Bioars S.A.,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan G.","family":"Abraldes","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Center of Excellence for Gastrointestinal Inflammation and Immunity Research,University of Alberta,Edmonton,Alberta,Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirna","family":"Biglione","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones Biom\u00e9dicas en Retrovirus y SIDA,CONICET\u2010Universidad de Buenos Aires,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Mauro","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit and Liver Unit,Hospital Italiano de Buenos. Aires.,Buenos Aires,Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"hep42034-bib-0001-20241127","article-title":"Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS\u2010CoV\u20102 infection","volume":"25","year":"2021","journal-title":"Ann Hepatol"},{"key":"hep42034-bib-0002-20241127","article-title":"Features of 20 133 UK patients in hospital with covid\u201019 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","year":"2020","journal-title":"BMJ"},{"key":"hep42034-bib-0003-20241127","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid\u2010organ transplant recipients","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"hep42034-bib-0004-20241127","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid\u2010 19 vaccine","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"hep42034-bib-0005-20241127","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector\u2010based heterologous prime\u2010boost COVID\u201019 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"hep42034-bib-0006-20241127","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS\u2010CoV\u20102 vaccination among liver transplant recipients","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"hep42034-bib-0007-20241127","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cgh.2021.09.003","article-title":"SARS\u2010CoV2\u2010specific humoral and T\u2010cell immune response after second vaccination in liver cirrhosis and transplant patients","volume":"20","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep42034-bib-0008-20241127","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2021.07.034","article-title":"Effectiveness of SARS\u2010Cov\u20102 vaccination in liver transplanted patients: the debate is open!","volume":"76","year":"2022","journal-title":"J Hepatol"},{"key":"hep42034-bib-0009-20241127","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2\u2010dose sars\u2010cov\u20102 mRNA vaccine series in solid organ transplant recipients","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"hep42034-bib-0010-20241127","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jhep.2021.09.037","article-title":"Reply to: Effectiveness of SARS\u2010Cov\u20102 vaccination in liver transplanted patients: the debate is open!","volume":"76","year":"2022","journal-title":"J Hepatol"},{"key":"hep42034-bib-0011-20241127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/lt.26351","article-title":"Clinical factors associated with lack of serological response to SARS\u2010CoV\u20102 mRNA vaccine in liver transplant recipients","volume":"28","year":"2022","journal-title":"Liver Transpl"},{"key":"hep42034-bib-0012-20241127","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS\u2010 CoV\u2010 2 infection","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"hep42034-bib-0013-20241127","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/TP.0000000000003850","article-title":"Antibody response to the Janssen COVID\u201019 vaccine in solid organ transplant recipients","volume":"105","year":"2021","journal-title":"Transplantation"},{"key":"hep42034-bib-0014-20241127","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/lt.26400","article-title":"Low immunoglobulin G antibody levels against severe acute respiratory disease coronavirus 2 after two\u2010dose vaccination among liver transplant recipients","volume":"28","year":"2022","journal-title":"Liver Transpl"},{"key":"hep42034-bib-0015-20241127","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","year":"2007","journal-title":"Lancet"},{"key":"hep42034-bib-0016-20241127","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV\u201019\/mRNA vaccination","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"hep42034-bib-0017-20241127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1\u2010S\u2010primed participants (CombiVacS): a multicentre, open\u2010label, randomised, controlled, phase 2 trial","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"hep42034-bib-0018-20241127","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA covid\u201019 vaccine in solid\u2010organ transplant recipients","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"hep42034-bib-0019-20241127","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1097\/TP.0000000000003934","article-title":"Antibody response to a fourth dose of a SARS\u2010CoV\u20102 vaccine in solid organ transplant recipients: a case series","volume":"105","year":"2021","journal-title":"Transplantation"},{"key":"hep42034-bib-0020-20241127","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1111\/ajt.16766","article-title":"Humoral and cellular immune response and safety of two\u2010dose SARS\u2010CoV\u20102 mRNA\u20101273 vaccine in solid organ transplant recipients","volume":"21","year":"2021","journal-title":"Am J Transpl"},{"key":"hep42034-bib-0021-20241127","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/hep4.1937","article-title":"Antibody response to the messenger RNA\u20101273 vaccine (Moderna) in liver transplant recipients","volume":"6","year":"2022","journal-title":"Hepatol Commun"},{"key":"hep42034-bib-0022-20241127","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jhep.2022.02.015","article-title":"Past COVID\u201019 and immunosuppressive regimens affect the long\u2010term response to anti\u2010SARS\u2010CoV\u20102 vaccination in liver transplant recipients","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"hep42034-bib-0023-20241127","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/ajt.16851","article-title":"Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS\u2010CoV\u20102 vaccination in kidney transplant recipients","volume":"22","year":"2022","journal-title":"Am J Transplant"},{"key":"hep42034-bib-0024-20241127","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1600-6143.2007.02066.x","article-title":"Influenza vaccination is efficacious and safe in renal transplant recipients","volume":"8","year":"2008","journal-title":"Am J Transplant"},{"key":"hep42034-bib-0025-20241127","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ki.2012.106","article-title":"Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination","volume":"82","year":"2012","journal-title":"Kidney Int"},{"key":"hep42034-bib-0026-20241127","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/ajt.12149","article-title":"Randomized controlled trial of high\u2010dose intradermal versus standard\u2010dose intramuscular influenza vaccine in organ transplant recipients","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"hep42034-bib-0027-20241127","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1086\/374784","article-title":"Randomized, double\u2010 blind, controlled trial of pneumococcal vaccination in renal transplant recipients","volume":"187","year":"2003","journal-title":"J Infect Dis"},{"key":"hep42034-bib-0028-20241127","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","year":"2005","journal-title":"Transplantation"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.2034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.2034","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:13:29Z","timestamp":1732709609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.2034","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"type":"print","value":"2471-254X"},{"type":"electronic","value":"2471-254X"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"2022-02-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}